Exploring Next-Generation ADCs: Future Insight for Dual Payload ADCs

• Showcasing traditional cytotoxic ADC development and combination of IO drug, headlined by the approval and success of Padcev
• Exploring next-generation ADCs delivering an immune agonist payload and their expansion toward next-generation immunostimulatory dual payload ADC
• Discussing a strategy for a next-generation ADC, challenges and solutions

Speakers:

Michinori Akaiwa

Head of Antibody-Drug Conjugate

Astellas